Who Owns LivaNova Company?

Who owns LivaNova?

The 2015 $2.7 billion cross-border merger of an Italian cardiovascular firm and an American neuromodulation company created LivaNova PLC, now a London-headquartered medtech leader split operationally between Europe and the US. Its strategy, governance and pivots are shaped by concentrated institutional ownership and activist investors.

Major ownership consists of large institutional holders and mutual funds controlling significant stakes, with the Board and activist voices influencing governance and strategic divestitures. See LivaNova Porter's Five Forces Analysis for product and market context.

Founders and early ownership of LivaNova PLC were shaped by the October 2015 merger between Sorin S.p.A. and Cyberonics, Inc., creating a transatlantic medical-device group with a dual heritage in cardiovascular and neuromodulation technologies. The initial equity split and leadership arrangement preserved both companies’ founding visions while setting governance for integration.

Merger equity split

At closing, former Cyberonics shareholders held about 54% and former Sorin shareholders held about 46% of LivaNova, reflecting relative market values.

Leadership balance

André‑Michel Ballester, ex‑Sorin CEO, became inaugural CEO; Dan Moore, ex‑Cyberonics CEO, served as non‑executive Chairman to preserve dual leadership perspectives.

Legacy backers

Sorin’s history included European private equity and industrial investors such as Mittel S.p.A. and Equinox; Cyberonics had a US institutional investor base as a NASDAQ company.

Shareholder protections

Initial agreements included executive lock‑ups and integration clauses to stabilize ownership and guard against immediate hostile bids during consolidation.

Market reaction

The merger was framed as both defensive and growth‑oriented in a consolidating healthcare market, with no major early ownership disputes reported.

Early investor rotation

Over the first years post‑merger, European retail shareholders from the Sorin side gradually rotated out, while US healthcare funds increased positions, reflecting interest in neuromodulation growth potential.

Early ownership and governance set the stage for subsequent shifts as founders retired and institutional investors altered the LivaNova ownership mix.

Founding ownership facts

Key factual points on the merger and early ownership dynamics.

• Merger closing: October 2015, forming LivaNova PLC with combined market cap reflective of both firms.
• Initial share split: former Cyberonics ~54%, former Sorin ~46%.
• Leadership: Ballester as CEO, Moore as non‑executive Chairman to balance corporate cultures.
• Investor profile shift: European private equity and retail from Sorin replaced progressively by US institutional healthcare funds.

For more on market positioning and target segments related to LivaNova ownership and strategy see Target Market of LivaNova

Complete LivaNova Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events shaping LivaNova ownership include its 2015 NASDAQ debut (ticker LIVN), the 2021 sale of the heart valve business to Corcym for $300,000,000, and activist interventions culminating in executive change and a refocus on higher-margin, technology-led therapies.

By Q1 2025 LivaNova ownership is highly institutionalized, with over 95% of shares held by professional investors and major holders including BlackRock, Vanguard, and Wellington driving corporate strategy and pipeline expectations.

LivaNova ownership snapshot (Q1 2025)

Top institutional investors and ownership trends that influence company decisions and valuation.

• BlackRock Inc.: approximately 14.2% (~7.6M shares)
• The Vanguard Group: approximately 10.8%
• Wellington Management: approximately 8.5%
• Other notable holders: State Street, Dimensional Fund Advisors (each ~3–5%)

Institutional concentration affects LivaNova shareholders and corporate structure; activist pressure from Elliott Investment Management accelerated governance changes and prioritized margin expansion for products such as VNS Therapy; see a concise company timeline in this Brief History of LivaNova.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The current Board of Directors of LivaNova comprises ten members, a majority of whom are independent and aligned with NASDAQ and UK governance standards; this one-share-one-vote company governance supports responsiveness to institutional investors and cross-border regulatory requirements.

The board refresh following activist pressure has increased expertise in US healthcare and turnaround execution, aligning with major institutional holders and reflecting the company's democratic share voting under a one-share-one-vote structure.

Board control and voting dynamics

Voting power at LivaNova is proportional to equity ownership with no dual-class shares; major institutional investors hold the largest influence.

• One-share-one-vote structure ensures alignment between ownership and control
• Major shareholders include large institutional investors such as BlackRock and Wellington (significant stakes reported in 2025 filings)
• Board composition now balances long-term strategy with activist demands for performance and transparency
• CEO Vladimir Makatsaria is the board's most influential executive voice after his 2024 appointment

For additional context on company strategy and revenue drivers that inform board decisions, see Revenue Streams & Business Model of LivaNova.

LivaNova Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Between 2023 and 2025 LivaNova ownership shifted toward greater institutional concentration and US-centric leadership, driven by management changes and tactical buybacks that narrowed share dispersion and aligned reporting with US investor expectations.

Share buybacks, executive departures from the Sorin era, and alignment with US GAAP have increased appeal to US-based LivaNova investors and reinforced expectations of strategic moves, including potential M&A interest from major medtech firms.

Leadership transition

Finalizing Vladimir Makatsaria’s 2024 appointment sharpened executive focus on neuromodulation and the OSPREY obstructive sleep apnea program.

Institutional concentration

Top five institutional holders controlled nearly 45% of shares by 2025, signalling confidence from major asset managers.

Share repurchase program

Late-2024 repurchases targeted dilution from employee options and communicated management’s view that the stock was undervalued given cardiopulmonary market position.

M&A outlook

Analysts in 2025–2026 flagged LivaNova as an acquisition candidate for conglomerates like Medtronic or Boston Scientific due to strong cardiopulmonary share and defensible neuromodulation patents.

For context on investor messaging and positioning that influenced ownership trends see Marketing Strategy of LivaNova

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE